We have used Heidenhain-pouch dogs to investigate the effects of (+/-)-5-methoxy-2-{[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sulph inyl}-1H-imidazo[4,5-
b]pyridine (TU-199), an
imidazopyridine derivative, on gastric acid secretion stimulated by
histamine,
carbachol and
tetragastrin. We have also investigated the duration of the antisecretory effect of
TU-199 using a measurement of intragastric pH for 24 h in
gastric fistula dogs whose gastric acid secretion was stimulated by
histamine. Single
oral administration of
TU-199 (0.1, 0.2 and 0.4mgkg(-1)) dose-dependently suppressed gastric acid secretion stimulated by
histamine infusion. Oral treatment with
TU-199 (0.2, 0.4 and 0.8 mg kg(-1)) also dose-dependently inhibited
acid secretion induced by
carbachol and
tetragastrin. The inhibitory effect of
TU-199 on stimulated gastric acid secretion was more potent than that of
omeprazole, a well-known H+,K(+)-
ATPase inhibitor in dogs. Repeated oral treatment with
TU-199 at a dose of 0.2 mg kg(-1) once a day for seven days markedly suppressed
histamine-stimulated gastric acid secretion in dogs. This inhibitory effect of
TU-199 reached a maximum level after three or four doses and was more pronounced than that of
omeprazole or
lansoprazole. In
gastric fistula dogs, the duration of intragastric pH-elevation by administration of
TU-199 (0.3 mg kg(-1)) was much longer than that of
omeprazole (0.6mgkg(-1)) or
lansoprazole (0.9mgkg(-1)). The IC50 values (doses resulting in 50% inhibition) of
TU-199,
omeprazole and
lansoprazole with regard to H+,K(+)-
ATPase activity in dog gastric mucosal microsomes were 8.6, 8.8 and 9.9 microM, respectively. These results indicate that
TU-199 inhibits gastric acid secretion via suppression of a H+,K(+)-
ATPase activity. Our findings also suggest that
TU-199 might have potent and long-lasting effects on gastric acid secretion.